Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus
Authors:
- 4 February 2012
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 90 (7) , 837-846
Abstract
Increasing evidences suggest that the type I interferon α (IFNα) plays a critical role in the etiopathogenesis of systemic lupus erythematosus (SLE), which makes it a promising therapeutic target for the treatment of the disease. By screening a large size non-immune human antibody library, we have developed a human single-chain antibody (ScFv) AIFNα1bScFv01 and corresponding whole antibody AIFNα1bIgG01 to human interferon α1b (IFNα1b) with high specificity and high affinity. The IgG antibody could down-regulate the expression of ISG15 and IFIT-1 induced by either recombinant IFNα1b or naïve IFNα from SLE patients’ sera, and reduced total serum IgG and IgM antibodies level in a pristane-primed lupus-like mouse model. The crystal structure of AIFNα1bScFv01-IFNα1b complex solved to 2.8 Å resolution revealed that both Pro26-Gln40 region in loop AB and Glu147-Arg150 region in helix E of IFNα1b contribute to binding with AIFNα1bScFv01. Four residues of above two regions (Leu30, Asp32, Asp35 and Arg150) are critical for the formation of antigen–antibody complexes. AIFNα1bScFv01 shares partial epitopes of IFNα1b with its receptor IFNAR2 but with much higher binding affinity to IFNα1b than IFNAR2. Thus, AIFNα1bIgG01 exhibits its neutralizing activity through competition with IFNAR2 to bind with IFNα and prevents the activation of IFNα-mediated signaling pathway. Our results highlight the potential use of the human antibody for modulating the activity of IFNα in SLE.Keywords
This publication has 31 references indexed in Scilit:
- The testosterone binding mechanism of an antibody derived from a naïve human scFv libraryJournal of Molecular Recognition, 2011
- Recent advances in the genetics of systemic lupus erythematosusExpert Review of Clinical Immunology, 2010
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- MolProbity: all-atom structure validation for macromolecular crystallographyActa Crystallographica Section D Structural Biology, 2009
- Type I interferon and lupusCurrent Opinion in Rheumatology, 2009
- How the study of children with rheumatic diseases identified interferon‐α and interleukin‐1 as novel therapeutic targetsImmunological Reviews, 2008
- Systemic Lupus ErythematosusNew England Journal of Medicine, 2008
- Iterative model building, structure refinement and density modification with thePHENIX AutoBuildwizardActa Crystallographica Section D Structural Biology, 2007
- BALBES: a molecular-replacement pipelineActa Crystallographica Section D Structural Biology, 2007
- OASISand molecular-replacement model completionActa Crystallographica Section D Structural Biology, 2007